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Potential Treatment of Polycystic Kidney Disease
with TNF-a Inhibitor
Dominant mutations in either PKD1 or PKD2 cause auto-
somal-dominant polycystic kidney disease (ADPKD), but
it has been proposed that a two-hit mechanism—in which
the remaining functional copy of the gene is somatically
inactivated—is required for cyst formation in this disease.
Arguing against this mechanism are the high rate at
which cyst formation occurs in mutation carriers and
the fact that hypomorphic alleles of Pkd1 are sufﬁcient
for cyst formation in mice. Li et al. announce TNF-a as
a nongenetic factor that might contribute to ADPKD, a re-
sult that suggests a potential pharmacologic intervention
for reducing cyst formation. In mice, the authors found
that TNF-a promotes cyst formation, particularly when
polycystin-2 levels are reduced. Mechanistically, treat-
ment of inner medullary collecting duct cells with TNF-a
altered the localization of polycystin-2 protein and
disrupted its interaction with polycystin-1, effects that ap-
peared to occur through the action of the TNF-a-induced
protein FIP2. The relevance of these ﬁndings is supported
by the fact that TNF-a, FIP2, and the TNF-a-converting
enzyme TACE accumulate in cyst ﬂuids of people with
ADPKD. Being as it is that an FDA-approved inhibitor of
TNF-a, etanercept, is available, Li et al. tested its effects
on cyst formation in mice. Etanercept prevented cyst for-
mation in Pkd2þ/ mice, yielding the hope that this drug
might be useful in preventing or slowing the progression
of cyst formation in individuals who carry ADPKD-associ-
ated mutations.
Li et al. (2008). Nature Medicine. Published online June 15,
2008. 10.1038/nm1783.
Metal Homeostasis in Alzheimer Disease
Despite having a variety of direct effects, many of the
drugs that are under development for the treatment of
Alzheimer disease (AD) are aimed at reducing b amyloid
(Ab) levels. One of the approaches targets brain metal
ions, particularly Cu and Zn, because some researchers
believe that disruption of their homeostasis is intimately
tied to AD pathogenesis. In support of this idea, Adlard
et al. ﬁnd that one such drug, the 8-hydroxy quinoline
PBT2, improves cognitive performance in two mouseThe Ammodels of AD within days of administration. But how ex-
actly does PBT2 work? The levels of several Ab species de-
crease in response to PBT2 treatment, but the only one
that is consistently signiﬁcant between both AD models
is soluble interstitial Ab, which means it could be the
key to PBT2’s utility in AD, and—more generally—that
it has a key role in the acute cognitive deﬁcits that are
ameliorated by treatment with PBT2. Comparisons of
the effects of PBT2 with the closely related drug clioqui-
nol, which has weaker effects on cognitive performance
in the mouse models, imply that the improved effects of
PBT2 are due to its increased abilities to promote uptake
of Zn and Cu, to cross the blood-brain barrier, and to in-
hibit the effects of excess metal binding to Ab. Beyond
suggesting that targeting Cu and Zn is a plausible ap-
proach for AD treatment, this work also highlights the
idea that some of the cognitive defects associated with
AD in mouse models are reversible.
Adlard et al. (2008). Neuron 59, 43–55. 10.1016/j.
neuron.2008.06.018.
Beyond BRCA
The availability of genetic testing for mutations in BRCA1
and BRCA2 has had major implications for many families
at high risk of breast cancer, a fact that is appreciated by
much of the general public. The subtlety that tends to
be underappreciated is this: Many families, even if they
are at high risk of breast cancer, don’t have mutations
in either of these two genes. So what is the relevance of
genetic testing for them? Could the common risk alleles
that have been discovered for breast cancer through ge-
nome-wide association studies over the past couple of
years provide the basis for genetic testing that would be
relevant in a general population? This is the question ex-
plored by Pharoah et al., who generated risk proﬁles based
on these common susceptibility alleles. The proﬁles sug-
gest that, other than distinguishing between women in
the highest and lowest risk groups, genetic testing for
these alleles would not sufﬁciently discriminate between
individuals in terms of breast cancer risk. For example,
the 20% of the population at highest risk of breast cancer
on the basis of this testing would account for less than
30% of breast cancer cases in the population. As addi-
tional susceptibility alleles are discovered, however, the1Department of Human Genetics, Emory University School of Medicine, Atlanta, GA 30322, USA
*Correspondence: kgarber@genetics.emory.edu
DOI 10.1016/j.ajhg.2008.07.012. ª2008 by The American Society of Human Genetics. All rights reserved.erican Journal of Human Genetics 83, 155–156, August 8, 2008 155
risk proﬁles predict that genetic testing will be able to dis-
criminate meaningful differences in risk for individuals.
Currently, the utility of this testing, as envisioned by
Pharoah et al., would be in the context of population-
based screening. Genetic testing could permit the imple-
mentation of more efﬁcient breast cancer screening
programs wherein women at higher risk have earlier or
more intense screening and those at lower risk may delay
or avoid further screening.
Pharoah et al. The New England Journal of Medicine 358,
2796–2803.
DNA Methylation Map
We know that regulation of gene expression through
DNA methylation is an essential process, and it has
been possible for some time to examine DNA methyla-
tion on a limited scale through the use of bifulphite
sequencing. Now Meissner et al. introduce reduced repre-
sentation bisulphate sequencing (RRBS), which allows
them to examine DNA methylation patterns on a geno-
mic scale, including sequences from an estimated 90% of
all CpG islands. Through RRBS, they compare, for exam-
ple, DNA methylation patterns for different types of cells
and promoters. They observe extensive changes to DNA
methylation patterns during cellular differentiation, and
they ﬁnd that DNA methylation patterns are more
closely correlated to histone methylation than to the un-
derlying DNA sequence content. Undoubtedly, using this
technique for further comparisons of DNA methylation
patterns will give us an even greater understanding of156 The American Journal of Human Genetics 83, 155–156, Augustthe process and the role of DNA methylation in gene
regulation.
Meissner et al. (2008). Nature. Published online July 6, 2008.
10.1038/nature07107.
Aging and DNA Methylation
While we’re on the subject of DNA methylation, work by
Bjornssen et al. looks at changes to DNA methylation with
age. It has been hypothesized that epigenetic changes asso-
ciatedwithagingcouldalter gene expressionandultimately
contribute to some of the common adult-onset genetic dis-
eases, but few data are available to prove that these age-re-
lated changes occur. In fact, Eckhardt et al. (NatureGenetics
[2006] 38, 1378–1385) grouped individuals by age and did
not ﬁnd evidence that DNA methylation changes over
time. Now Bjornsson et al. have been able to examine
DNA methylation on an individual level. Using two data
sets in which blood samples were collected from the same
individuals several years apart, they ﬁnd evidence that
global increases or decreases inDNAmethylation can occur
over a period of several years. Themagnitude and direction
of the change in DNA methylation tends to be similar be-
tweenmembers of the same family, indicating thatmainte-
nanceof themethylationpattern is aheritable trait. Because
global DNA methylation decreased in approximately the
samenumber of people as it increased, averaging the results
across different age groups would neutralize the effects ob-
served on an individual level, thus providing a likely expla-
nation for the negative result of the previous work.
Bjornsson et al. (2008). JAMA 299, 2877–2883.8, 2008
